Blood Pressure Medication Recall: What You Need to Know

A recall of certain blood pressure medications has been issued in the United States, prompting questions for patients regarding the safety and efficacy of their prescriptions. The recall involves specific lots of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide tablets manufactured by New Jersey-based Macleods Pharma USA, according to the U.S. Food and Drug Administration (FDA).

Why it is trending now

The recall is currently trending as patients seek to verify if their personal medication is affected by federal quality standard failures. The FDA reports that the affected tablets failed to meet dissolution specifications, meaning the medication may not dissolve in the body as intended when taken.

Key facts

• The recall includes 3,528 bottles of 30-count tablets (Lot 12251163A) and 216 bottles of 90-count tablets (Lot 12251163B), as reported by Fox Business.
• Affected 30-count bottles are identified by NDC 33342-246-07, while the 90-count bottles are labeled with NDC 33342-246-10.
• Both identified lots have an expiration date of May 31, 2027, according to the FDA.
• Consumers are advised to check their prescription labels for these specific lot numbers and National Drug Codes to determine if their medication is subject to the recall.

Why this is trending in United Kingdom

While the recall is specific to the United States market, the topic is trending in the United Kingdom as international news regarding pharmaceutical safety often draws significant attention from British readers who monitor global health alerts.

Background and context

Pharmaceutical recalls occur periodically when products fail to meet strict manufacturing or quality control standards set by regulators like the FDA. Dissolution testing is a standard requirement for oral medications to ensure that the active ingredients are released into the system at the correct rate to provide the intended therapeutic benefit.

What happens next

Patients who find they possess the recalled medication should contact their pharmacist or healthcare provider to discuss next steps, such as obtaining a safe replacement. It is not confirmed how many of the affected bottles have reached consumers or if there have been any reports of adverse health effects linked to these specific lots at the time of writing.